WAVE Life Sciences (NASDAQ:WVE – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03), FiscalAI reports. WAVE Life Sciences had a negative return on equity of 56.76% and a negative net margin of 255.70%.The business had revenue of $2.27 million for the quarter, compared to analyst estimates of $7.45 million.
Here are the key takeaways from WAVE Life Sciences’ conference call:
- WVE-007 obesity development advanced into Phase IIa with dosing underway in patients with higher BMI and comorbidities. The company is also planning combination-with-incretin and post-incretin maintenance studies this year, targeting fat loss with muscle preservation and potentially once- or twice-yearly dosing.
- WVE-006 produced data the company says support treatment of both lung and liver manifestations of AATD with infrequent subcutaneous dosing. The FDA granted a meeting expected later this summer to discuss a potential accelerated-approval pathway, while data from the 600 mg cohort are expected in the second half of 2026.
- Wave remains on track to submit a CTA for WVE-008 in PNPLA3 liver disease in 2026. The RNA-editing program aims to restore functional protein rather than silence the target, with preclinical data showing more than 50% editing and reduced lipid accumulation versus siRNA.
- The company is exploring partnerships for its DMD candidate WVE-N531 before filing an NDA, citing an evolving regulatory and commercial landscape. Management said it continues to believe in the program but will reassess filing plans based on regulatory developments and partnership progress.
- Second-quarter revenue fell to $2.3 million from $8.7 million a year earlier, while the net loss widened to $69.4 million from $50.5 million as R&D and G&A spending increased. Wave ended the quarter with $490.6 million in cash and expects funding into Q3 2028, excluding potential future GSK milestone payments.
WAVE Life Sciences Stock Down 0.9%
Shares of NASDAQ:WVE traded down $0.05 during midday trading on Thursday, reaching $5.76. The company’s stock had a trading volume of 3,032,883 shares, compared to its average volume of 2,240,663. The stock has a fifty day moving average of $5.99 and a 200 day moving average of $9.00. WAVE Life Sciences has a twelve month low of $5.02 and a twelve month high of $21.73. The firm has a market capitalization of $1.11 billion, a PE ratio of -5.43 and a beta of -1.29.
Analyst Ratings Changes
Read Our Latest Analysis on WVE
Institutional Investors Weigh In On WAVE Life Sciences
Hedge funds have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its position in WAVE Life Sciences by 1.5% during the 4th quarter. Deutsche Bank AG now owns 95,706 shares of the company’s stock worth $1,627,000 after purchasing an additional 1,441 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of WAVE Life Sciences by 645.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after buying an additional 1,942 shares during the period. Nebula Research & Development LLC lifted its holdings in shares of WAVE Life Sciences by 8.7% in the 2nd quarter. Nebula Research & Development LLC now owns 34,342 shares of the company’s stock valued at $223,000 after buying an additional 2,748 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of WAVE Life Sciences by 7.7% in the third quarter. Envestnet Asset Management Inc. now owns 39,847 shares of the company’s stock worth $292,000 after buying an additional 2,866 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of WAVE Life Sciences by 44.8% in the second quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock worth $76,000 after buying an additional 3,609 shares during the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.
WAVE Life Sciences Company Profile
WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.
The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.
Featured Stories
- Five stocks we like better than WAVE Life Sciences
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
